Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What Genedrive (LSE:GDR) Is Signalling to the FTSE AIM All Share Index After a Busy Year

Genedrive develops rapid genetic tests designed to be run near the patient rather than in a central laboratory. Its best-known product, the MT-RNR1 ID Kit, identifies newborns carrying a genetic variant that makes them vulnerable to hearing loss if treated with certain antibiotics, allowing …

Ankur Sharma | 08 October 2026

Why GENinCode (LSE:GENI) Is Under the Spotlight on the FTSE AIM All Share Index

GENinCode develops polygenic and genetic risk assessment tests aimed at the prevention of cardiovascular disease, including the CARDIO inCode-Score coronary artery disease polygenic risk score and LIPID inCode for familial hypercholesterolaemia. It also offers ROCA, an ovarian cancer risk algorithm. The group operates in …

Ankur Sharma | 08 October 2026

FTSE AIM All-Share: Why CelLBxHealth plc (LSE:CLBX) Shares fell 1.96% on 8 October 2026

CelLBxHealth plc (LSE:CLBX) fell 1.96% on 8 October 2026, putting the stock among the weaker movers in the UK small-cap market shown in the day's trading list.

Ankur Sharma | 08 October 2026

FTSE AIM All-Share: Why Kromek Group plc (LSE:KMK) Shares fell 1.97% on 8 October 2026

Kromek Group plc (LSE:KMK) fell 1.97% on 8 October 2026, putting the stock among the weaker movers in the UK small-cap market shown in the day's trading list.

Ankur Sharma | 08 October 2026

GENinCode PLC (LSE:GENI) Slides 3.89% on 8 October 2026: Why the AIM Stock Is in Focus and What Investors Watch Next

Investors are assessing commercial adoption of genetic testing and healthcare reimbursement.

Ankur Sharma | 08 October 2026

Genedrive Plc (LSE:GDR) Slides 3.47% on 8 October 2026: Why the AIM Stock Is in Focus and What Investors Watch Next

Investors are assessing clinical adoption and healthcare procurement.

Ankur Sharma | 08 October 2026

Thalia Therapeutics PLC (LSE:THAT) Slides 4.00% on 8 October 2026: Why the AIM Stock Is in Focus and What Investors Watch Next

Investors are assessing the September interim results, the SanmirnaAcquisitionand the miRisten clinical programme.

Ankur Sharma | 08 October 2026

Why Is OptiBiotix Health (LSE:OPTI) Down 1.69% Today Despite Improving Revenue and Margins?

OptiBiotix is in focus because its investment case is moving from research-led development towards commercialisation. Revenue growth, improving gross profit and lower costs are important signals for a small healthcare company seeking to scale internationally. The company remains exposed to the pace at which …

Ankur Sharma | 08 October 2026
Support

Hi! How can we help you today?

Loading…